Dapiglutide is an investigational oral incretin receptor agonist developed as a synthetic peptide hormone analogue to treat obesity by regulating energy balance and glucose metabolism via the GLP-1 receptor.… Read more
Dapiglutide is an investigational oral incretin receptor agonist developed as a synthetic peptide hormone analogue to treat obesity by regulating energy balance and glucose metabolism via the GLP-1 receptor. To support the rigorous analytical requirements of its clinical development, pharmaceutical researchers rely on a comprehensive range of Dapiglutide reference standards, including the active pharmaceutical ingredient, identified process-related and degradation impurities, and relevant metabolites. Additionally, stable isotope labelled compounds are available to serve as high-precision internal standards in mass spectrometry-based assays. These high-purity materials are essential for accurate impurity profiling, method validation, and ongoing quality control, ensuring that analytical procedures reliably detect and quantify trace-level components throughout preclinical and clinical testing phases. By utilizing these characterized standards, laboratories can maintain regulatory compliance and verify the structural integrity of the drug substance.